Francesco Bianchi Acquires Shares of LivaNova PLC

On June 15, 2026, Francesco Bianchi purchased 2,383 shares of LivaNova PLC, a medical technology company listed on NasdaqGS under the ticker LIVN. This insider transaction did not involve a planned purchase and the shares were acquired at a market price of $79.48.

Insider Buying and Selling at LivaNova PLC

Several insiders were active on June 15, 2026. Francesco Bianchi bought 2,383 shares without a disclosed price and also sold 4,042 shares. Ahmet Tezel, Chief Innovation Officer, acquired 2,965 shares. Meanwhile, Donald Zurbay sold 308 shares at $79.70. These activities were not part of any pre-planned trading programs.

Other Institutional Activity in LivaNova

BlackRock, Inc. reduced its holdings by 184,614 shares, ending with 7,138,908 shares valued at approximately $453.7 million. Primecap Management Co/CA/ also trimmed its position by 17,800 shares to 4,207,052 shares, worth $267.4 million. In contrast, FMR LLC significantly increased its stake by 2,620,791 shares, bringing its total to 2,666,674 shares valued at $169.5 million. AQR Capital Management LLC added 339,230 shares, reaching a total of 2,494,372 shares worth about $154.4 million.

LivaNova Stock Snapshot

Shares of NasdaqGS:LIVN traded around $79.48. LivaNova has a market cap of $4.31 billion, a P/E ratio of 40.05, and a forward P/E of 16.95. The stock's 52-week range is between $41.02 and $80.96, with a 50-day moving average of $69.67 and a 200-day moving average of $62.48. The company's current ratio is 1.33, and it has a quick ratio of 1.009, with a debt-to-equity ratio of 28.35.

Recent Earnings

LivaNova reported revenue of $1.43 billion, reflecting a growth of 14.3%. The company achieved a net margin of 7.48% and a return on equity of 9.54%. Earnings per share stood at $1.96. The next earnings release is scheduled for August 5, 2026.

Analysts Set New Price Targets

On May 7, 2026, Barclays maintained a 'hold' rating with a $76.00 price target, while Mizuho and Baird maintained 'buy' ratings with targets of $90.00 and $76.00, respectively. Overall, analysts have a consensus 'buy' rating with a mean price target of $80.60, based on 10 analyst opinions.

About LivaNova

LivaNova PLC, headquartered in London, is a medical technology company that designs and sells medical devices. It operates in the Cardiopulmonary and Neuromodulation segments, offering products like heart-lung machines and VNS Therapy Systems. The company serves healthcare professionals and institutions worldwide. Led by CEO Vladimir A. Makatsaria, LivaNova employs around 3,300 people.

Bottom Line

Francesco Bianchi's recent purchase of LivaNova shares highlights insider confidence in the company. Investors often track such insider activities as they can provide insights into how company leaders view the firm's prospects. It's important to remember that this insider activity report is based on past events and may not reflect the current situation.